PTX and Contrast Induced Nephropathy

¬¬A randomized double blind placebo controlled trial examining the effects of Pentoxifylline on Contrast Induced Nephropathy reduction after percutaneous coronary intervention in high risk candidates

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016111530905N1

Enrollment

110

Registered

2017-03-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients candidate for percutaneous coronary intervention. ???????? ???? ??? ?????? ???? ??????? ???? ??????? ? ??????

Interventions

Intervention 1: placebo capsules plus N-acetyl cysteine. Intervention 2: Pentoxifylline plus N-acetyl cysteine.

Treatment - Drugs

placebo capsules plus N-acetyl cysteine

Pentoxifylline plus N-acetyl cysteine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion was only Mehran score more than or equal to 11. Exclusion criteria included need for urgent coronary angiography in the first 48 hours after admission, history of contrast media usage in previous 14 days or renal failure in recent six months, multiple myeloma, pregnancy or breastfeeding and pre-planned use of any other measure for CIN prevention apart from PTX consumption.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Contrast Induced Nephropathy. Timepoint: once. Method of measurement: 48 hours after angiography.	—

Secondary

Measure	Time frame
Cratinine. Timepoint: before and 48 hours after the intervention. Method of measurement: Laboratory unit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Farnaz Barzi

School of Medicine, ShahidBeheshti University of Medical Sciences

farnazbarzi@sbmu.tums.ac.ir+98 21 73430

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026